We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 25, 2021

Efficacy and Safety of Cabazitaxel vs Abiraterone/Enzalutamide in Older Patients With mCRPC in the CARD Study

European Urology


Additional Info

European Urology
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study
Eur Urol 2021 Jul 14;[EPub Ahead of Print], CN Sternberg, D Castellano, J de Bono, K Fizazi, B Tombal, C Wülfing, G Kramer, JC Eymard, A Bamias, J Carles, R Iacovelli, B Melichar, Á Sverrisdóttir, C Theodore, S Feyerabend, C Helissey, EM Poole, A Ozatilgan, C Geffriaud-Ricouard, R de Wit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading